60 related articles for article (PubMed ID: 27670568)
1. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
2. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
3. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
4. Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid.
Lee-Saxton YJ; Palacardo F; Greenberg JA; Egan CE; Marshall TE; Tumati A; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):215-220. PubMed ID: 38563429
[TBL] [Abstract][Full Text] [Related]
5. Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer.
Mao Y; Lin R; Wang Y; Yu J
Quant Imaging Med Surg; 2024 May; 14(5):3665-3675. PubMed ID: 38720856
[TBL] [Abstract][Full Text] [Related]
6. Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study.
He T; Li M; Gao ZL; Li XY; Zhong HR; Ding CS; Cai HW
Nucl Med Commun; 2024 Jun; ():. PubMed ID: 38832411
[TBL] [Abstract][Full Text] [Related]
7. The value of the first postoperative diagnostic I-131 scan in patients with papillary thyroid carcinoma.
Ran B; Shang J; Chen Y; Zhou M; Li H; He W; Li Y; Cai Q; Guo B; Gong J; Xu H
J Cancer Res Clin Oncol; 2024 Feb; 150(2):80. PubMed ID: 38319395
[TBL] [Abstract][Full Text] [Related]
8. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
[TBL] [Abstract][Full Text] [Related]
9. Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.
Wallner LP; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Lubitz C; Hawley ST; Haymart MR
J Clin Endocrinol Metab; 2021 May; 106(6):e2402-e2412. PubMed ID: 33687063
[TBL] [Abstract][Full Text] [Related]
10. Trends in radioactive iodine treatment after total thyroidectomy in Italy, 2001-2018.
Dal Maso L; Pierannunzio D; Francisci S; De Paoli A; Toffolutti F; Vaccarella S; Franceschi S; Elisei R; Fedeli U
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37256604
[TBL] [Abstract][Full Text] [Related]
11. Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview.
Singh NK; Ramamourthy B; Hage N; Nagaraju S; Kappagantu KM
Curr Radiopharm; 2024; 17(1):2-6. PubMed ID: 37877561
[TBL] [Abstract][Full Text] [Related]
12. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer.
Wallner LP; Reyes-Gastelum D; Hamilton AS; Ward KC; Hawley ST; Haymart MR
J Clin Oncol; 2019 Aug; 37(24):2152-2161. PubMed ID: 31283406
[TBL] [Abstract][Full Text] [Related]
13. Use of radioactive iodine for thyroid cancer.
Haymart MR; Banerjee M; Stewart AK; Koenig RJ; Birkmeyer JD; Griggs JJ
JAMA; 2011 Aug; 306(7):721-8. PubMed ID: 21846853
[TBL] [Abstract][Full Text] [Related]
14. Hemithyroidectomy in Papillary Thyroid Cancers: A Prospective, Single Institutional Surgical Audit and Contemplating on the Clinical Implications of 2015 American Thyroid Association Guidelines.
Rathod R; Panda NK; Bakshi J; Nayak G; Ramavat A
Indian J Otolaryngol Head Neck Surg; 2023 Jun; 75(2):508-516. PubMed ID: 37275097
[TBL] [Abstract][Full Text] [Related]
15. Variability in Thyroid Cancer Multidisciplinary Team Meeting Recommendations Is Not Explained by Standard Variables: Outcomes of a Single Centre Review.
Fenton ME; Wade SA; Pirrili BN; Balogh ZJ; Rowe CW; Bendinelli C
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575260
[TBL] [Abstract][Full Text] [Related]
16. Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Head Neck; 2024 Apr; ():. PubMed ID: 38572629
[TBL] [Abstract][Full Text] [Related]
17. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study.
Kuba S; Yamanouchi K; Hayashida N; Maeda S; Adachi T; Sakimura C; Kawakami F; Yano H; Matsumoto M; Otsubo R; Sato S; Fujioka H; Kuroki T; Nagayasu T; Eguchi S
Int J Surg; 2017 Feb; 38():143-148. PubMed ID: 27677707
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
19. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer.
Wang X; Zhu J; Li Z; Wei T
PLoS One; 2020; 15(6):e0234843. PubMed ID: 32542018
[TBL] [Abstract][Full Text] [Related]
20. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.
Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R
BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
